Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2024

  1. Targetable domains for the design of peptide-dendrimer inhibitors of SARS-CoV-2

    International Journal of Pharmaceutics, Vol. 661

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

2016

  1. Novel water-soluble mucoadhesive carbosilane dendrimers for ocular administration

    Molecular Pharmaceutics, Vol. 13, Núm. 9, pp. 2966-2976

2015

  1. HIV-1 reservoir dynamics after vaccination and antiretroviral therapy interruption are associated with dendritic cell vaccine-induced T cell responses

    Journal of Virology, Vol. 89, Núm. 18, pp. 9189-9199

2009

  1. Highly efficient transfection of rat cortical neurons using carbosilane dendrimers unveils a neuroprotective Role for HIF-1α in early chemical hypoxia-mediated neurotoxicity

    Pharmaceutical Research, Vol. 26, Núm. 5, pp. 1181-1191

2008

  1. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes

    Journal of Controlled Release, Vol. 132, Núm. 1, pp. 55-64